Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 2/20 | 0.36 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13383861 | 0.83 | KDM4E (0.39) | ACEKDM4EALDH1A1 | |
| SCHEMBL3281359 | 0.81 | ACE (0.48) | ACE | |
| SCHEMBL7543963 | 0.81 | ACE (0.48) | ACE | |
| SCHEMBL10691419 | 0.75 | PLA2G10 (0.43) | PLA2G10PLA2G5ACE | |
| SCHEMBL10913716 | 0.74 | PLA2G10 (0.43) | PLA2G10PLA2G5ACEALDH1A1 | |
| SCHEMBL10895110 | 0.74 | PLA2G10 (0.43) | PLA2G10PLA2G5ACEALDH1A1 | |
| SCHEMBL10792820 | 0.74 | PLA2G10 (0.38) | PLA2G10PLA2G5ACEALDH1A1 | |
| SCHEMBL10914477 | 0.74 | PLA2G10 (0.38) | PLA2G10PLA2G5KDM4EALDH1A1 | |
| SCHEMBL10913722 | 0.74 | PLA2G10 (0.43) | PLA2G10PLA2G5ACEALDH1A1 | |
| SCHEMBL10914780 | 0.74 | PLA2G10 (0.43) | PLA2G10PLA2G5ACEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020086994-A1 | Acylmercaptoalkanoylamino lactam esters or acids are converted to the corresponding mercaptoalkanoylamino lactam ester or acid under basic conditions using an agent that minimizes amount of disulfides | KRONENTHAL DAVID R (US) | 2002-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086994-A1 | Acylmercaptoalkanoylamino lactam esters or acids are converted to the corresponding mercaptoalkanoylamino lactam ester or acid under basic conditions using an agent that minimizes amount of disulfides | MPST, PTMS, TST | PLA2G10 1180/4885PLA2G5 1196/4885ACE 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.